stoxline Quote Chart Rank Option Currency Glossary
  
Bio-Rad Laboratories, Inc. (BIO)
302.61  7.09 (2.4%)    07-12 14:22
Open: 297.57
High: 304.28
Volume: 110,811
  
Pre. Close: 295.52
Low: 297.54
Market Cap: 8,642(M)
Technical analysis
2024-07-12 1:49:41 PM
Short term     
Mid term     
Targets 6-month :  355.39 1-year :  415.1
Resists First :  304.27 Second :  355.39
Pivot price 278.78
Supports First :  278.22 Second :  262.11
MAs MA(5) :  285.6 MA(20) :  280.81
MA(100) :  302.97 MA(250) :  325.79
MACD MACD :  0.3 Signal :  -2.6
%K %D K(14,3) :  82.5 D(3) :  61.8
RSI RSI(14): 66.1
52-week High :  431.79 Low :  261.58
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BIO ] has closed above the upper band by 9.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 25% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 295.96 - 297.1 297.1 - 298.41
Low: 280.77 - 281.98 281.98 - 283.36
Close: 293.21 - 295.2 295.2 - 297.49
Company Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Headline News

Fri, 12 Jul 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Thu, 11 Jul 2024
DAVENPORT & Co LLC Buys Shares of 44,353 Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat

Wed, 10 Jul 2024
Easterly Investment Partners LLC Trims Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat

Wed, 10 Jul 2024
Commonwealth Equity Services LLC Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World

Mon, 08 Jul 2024
Bio-Rad Launches System for Benchtop Gel and Western Blot Imaging - Technology Networks

Wed, 08 May 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 23 (M)
Shares Float 20 (M)
Held by Insiders 15.1 (%)
Held by Institutions 79.8 (%)
Shares Short 868 (K)
Shares Short P.Month 653 (K)
Stock Financials
EPS -10.69
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 317.32
Profit Margin -12.4 %
Operating Margin 8.4 %
Return on Assets (ttm) 1.6 %
Return on Equity (ttm) -3.5 %
Qtrly Rev. Growth -9.9 %
Gross Profit (p.s.) 0
Sales Per Share 111.3
EBITDA (p.s.) 21.44
Qtrly Earnings Growth 479.7 %
Operating Cash Flow 347 (M)
Levered Free Cash Flow 121 (M)
Stock Valuations
PE Ratio -28.29
PEG Ratio 1.4
Price to Book value 0.95
Price to Sales 2.71
Price to Cash Flow 20.45
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android